

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

Request for Coverage of Restricted Proton Pump Inhibitors (PPIs)

PATIENT INFORMATION			
PATIENT SURNAME	PATIENT GIVEN NAME	HEALTH CARD NUMBER	DATE OF BIRTH
PATIENT ADDRESS			
DRUG & DOSAGE REQUESTED			
Above standard dose omeprazole, or pantoprazole sodium			
<input type="checkbox"/> Omeprazole _____ mg _____ <input type="checkbox"/> Pantoprazole sodium _____ mg _____			
Coverage duration: 8 week trial, followed by up to one year of coverage Note: omeprazole and pantoprazole sodium are <u>regular benefits</u> at the standard daily doses (maximum 425 tablets/capsules per year)			
Standard dose of <u>restricted</u> PPIs			
<input type="checkbox"/> Lansoprazole _____ mg _____ <input type="checkbox"/> Pantoprazole Magnesium (Tecta) _____ mg _____			
Coverage duration: yearly coverage			
PPI MEDICATION HISTORY			
Agents Tried:		Dose, length of therapy, and outcome: (i.e., inadequate symptom control, wearing off, etc.)	
<input type="checkbox"/> Omeprazole	_____		
<input type="checkbox"/> Rabeprazole	_____		
<input type="checkbox"/> Pantoprazole sodium	_____		
<input type="checkbox"/> Pantoprazole magnesium	_____		
<input type="checkbox"/> Lansoprazole	_____		
<input type="checkbox"/> Other	_____		
DIAGNOSIS			
<input type="checkbox"/> Symptomatic GERD		<input type="checkbox"/> Peptic Ulcer Disease (gastric, duodenal ulcers)	
<input type="checkbox"/> Erosive Esophagitis, Barrett's Esophagus		<input type="checkbox"/> Other _____	
For double dose requests, please check that the following points have been considered: <i>(Strategies proposed in consultation with Gastroenterology Capital Health for optimal response to PPIs)</i>			
<input type="checkbox"/> PPI is being taken minutes prior to breakfast, on an empty stomach (before ANY food or drink)			
<input type="checkbox"/> No food or drink after the main evening meal (at least 2 hours before going to bed)			
<input type="checkbox"/> Other causes of gastric upset (NSAIDs, bisphosphonates, etc.) have been considered			
Please note that recent evidence ^{1,2} has raised concerns about the extensive use of double dose PPIs. The concerns include:			
<ul style="list-style-type: none"> • The lack of a clinically significant benefit double dose has over standard dose for many conditions • Potential adverse effects with PPI use (e.g., observational data suggesting increased risk for Clostridium difficile infections, pneumonia, hip fractures, and gastric polyps) which have occurred with both standard and higher doses • Increased cost 			
<small>1. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) PPI therapy 2007 http://www.cadth.ca/index.php/en/compus/ppis 2. Dalhousie Academic Detailing PPIs: Burning Questions 2008 http://cme.medicine.dal.ca/ad_resources.htm#ppi </small>			
PRESCRIBER NAME & ADDRESS: <div style="text-align: center; border-top: 1px solid black; margin-top: 10px;">LICENCE #</div>		<div style="text-align: center; border-top: 1px solid black; margin-top: 10px;">PRESCRIBER SIGNATURE</div> <div style="text-align: center; border-top: 1px solid black; margin-top: 10px;">DATE</div>	

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs
 P.O. Box 500, Halifax, NS B3J 2S1
 Fax: (902) 496-4440